# A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

> **NCT00148486** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 261 (—)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** NS 2330

## Key facts

- **NCT ID:** NCT00148486
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-03
- **Final completion:** —
- **Target enrollment:** 261 (—)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148486, "A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00148486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*